Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05960578 · ClinicalTrials.gov registry record · Phase 2

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

A Phase 2 study of Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
8
Enrollment target
1
Study location

NCT05960578 is a Phase 2 study of Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8 that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 8 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05960578, a Phase 2 study of Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may work better in treating patients with castration-resistant prostate cancer.

Conditions Studied

Prostate Adenocarcinoma Stage IV Prostate Cancer AJCC v8 Metastatic Castration-resistant Prostate Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • DRUG Apalutamide
  • DRUG Golimumab

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-05-23
Est. Completion 2026-04-07
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05960578

The ClinicalTrials.gov registry entry for NCT05960578 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (96% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05960578 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT05960578 about?

NCT05960578 is a clinical study titled "Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study". This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflamma...

What is the current status of trial NCT05960578?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2024-05-23. Estimated completion is 2026-04-07.

What conditions does trial NCT05960578 study?

This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma.

What interventions are being tested in trial NCT05960578?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Apalutamide (DRUG), Golimumab (DRUG).

Who is sponsoring clinical trial NCT05960578?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05960578 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Adenocarcinoma

All registered trials for this condition

Stage IV Prostate Cancer AJCC v8

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.